Veeva Sys Inc Stock Price, News & Analysis

Veeva (NYSE: VEEV) will present at the Raymond James 2025 TMT and Consumer Conference in New York on Monday, December 8, 2025 at 11:20 a.m. ET. Presenters will be Brian Van Wagener, CFO, and Paul Shawah, EVP Strategy. The presentation will be available via live webcast, with an archived replay posted afterward on Veeva's investor relations site.

Investors can access the live and archived webcast at https://ir.veeva.com.

Veeva Systems (NYSE: VEEV) announced on December 3, 2025 that Veeva AI Agents are now available for Vault CRM and PromoMats, delivering industry-specific AI inside Veeva applications.

Initial agents include Free Text Agent, Voice Agent, and Pre-call Agent for Vault CRM, plus Quick Check Agent and Content Agent for PromoMats. Agents operate with direct, secure access to data within existing permissions and audit trails, and customers can configure or build custom agents. Additional agents for clinical, regulatory, safety, quality, medical, and commercial are planned throughout 2026. Veeva Business Consulting will support process design and change management as customers adopt agents.

Veeva Systems (NYSE: VEEV) announced that Roche Pharmaceuticals will extend its partnership by adopting Veeva Vault CRM across Roche's global pharma organization, expanding Veeva's commercial footprint.

The announcement highlights that Veeva AI — described as agentic, industry-specific AI — will power Vault CRM with four planned AI agents: Free Text Agent, Voice Agent, Pre-call Agent, and Media Agent, which are planned for availability in December 2025.

The release frames the move as enabling more personalized HCP interactions and improved insights for field teams, without disclosing financial terms or contract value.

Veeva (NYSE: VEEV) reported fiscal 2026 third quarter results for the period ended October 31, 2025: Total revenues $811.2M (up 16% YoY) and Subscription services $682.5M (up 17% YoY). Operating income was $240.9M (+33% YoY) and non-GAAP operating income was $364.9M (+20% YoY). Net income was $236.2M (+27% YoY) and non-GAAP net income was $345.1M (+20% YoY).

Veeva highlighted progress on Veeva AI, Vault CRM customer additions, and Development Cloud wins. Guidance: Q4 revenue $807–$810M; FY revenue $3,166–$3,169M; non-GAAP FY diluted EPS ~$7.93.

Veeva Systems (NYSE: VEEV) announced on November 4, 2025 that more than 100 biotechs across 60 companies have adopted Veeva Basics to standardize clinical, regulatory, and quality operations. Veeva Basics uses pre-configured, pre-validated applications on the Vault Platform for fast deployment and seamless upgrade to full Vault solutions.

Two new applications—Veeva LIMS Basics and Veeva PromoMats Basics—are planned for availability in early 2026, with stability functionality for LIMS planned for 2026. More information at veevabasics.com.

Veeva Systems (NYSE: VEEV) will release its fiscal 2026 third quarter results for the period ending October 31, 2025, after market close on November 20, 2025. A live conference call and webcast will be held at 2:00 p.m. PT / 5:00 p.m. ET that day to discuss results.

Prepared remarks will be posted to the investor relations site at approximately 1:05 p.m. PT / 4:05 p.m. ET, and a webcast replay will be available on the same site after the live event. Registration is required for the conference call.

Veeva Systems (NYSE: VEEV) and OpenEvidence announced a long-term partnership on Oct. 16, 2025 to jointly create and market Open Vista, an AI platform aimed at increasing patient access to clinical trials, accelerating drug discovery, and improving adoption of approved medicines for better outcomes.

OpenEvidence said >40% of U.S. physicians use its point-of-care clinical decision support AI. Veeva and OpenEvidence expect the first Open Vista product offerings to be released in 2026.

Veeva (NYSE: VEEV) announced that Veeva AI Agents will begin rolling out December 2025 for commercial use, with staged availability across R&D and quality through 2026. Agents are built into the Veeva Vault Platform, provide application-specific prompts and safeguards, and have secure access to Veeva data, documents, and workflows.

Planned availability: Dec 2025 Vault CRM & PromoMats; Apr 2026 Safety & Quality; Aug 2026 Clinical Operations, Regulatory, Medical; Dec 2026 Clinical Data. Veeva AI uses LLMs from Anthropic and Amazon (Bedrock); custom agents can use Veeva-hosted or customer models on Amazon Bedrock or Microsoft Azure AI Foundry. Pricing is usage-based.

Veeva Systems (NYSE:VEEV) released industry research revealing significant challenges in clinical data management. The study found that two-thirds of data managers and clinical research associates (CRAs) believe current inefficiencies threaten future data quality.

Key findings show that data managers spend over 12 hours per week per study on manual data reconciliation, with 97% performing reconciliation outside clinical systems. Major inefficiencies stem from manual data re-entry (68%), disconnected systems (59%), and inefficient workflows (58%).

The research highlights that 71% of data managers expect increased automation in data cleaning over the next two years, while 81% believe connecting clinical systems would improve study execution. However, challenges persist, including protocol complexity (58%), resource constraints (57%), and change resistance (48%).